Squarepoint’s Sage Therapeutics SAGE Stock Holding History

Squarepoint’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-19,000	Closed	-$356K	–	4571
2024 Q1	$356K	Buy	+19,000	New	+$438K	﹤0.01%	3276
2023 Q1	–	Sell	-12,100	Closed	-$461K	–	3749
2022 Q4	$461K	Hold	12,100	–	–	﹤0.01%	2327
2022 Q3	$474K	Buy	+12,100	New	+$468K	﹤0.01%	2227

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Squarepoint's SAGE Position: Q3 2025 in Review

Squarepoint sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 19,389 shares — an estimated $177K sold.

Squarepoint first reported a position in SAGE in Q3 2015 and held it in 30 quarters. The position peaked at $9.48M in Q2 2018. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Squarepoint reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Squarepoint sold 19,389 Sage Therapeutics shares in Q3 2025, an estimated $177K.
Squarepoint first reported a position in Sage Therapeutics in Q3 2015 and held it in 30 quarters.
Squarepoint's Sage Therapeutics position peaked at $9.48M in Q2 2018.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.